Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FFP-106
- Development stage
- Discontinued
- Lead developer
- Fast Forward Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
FFP-106 is a bispecific monoclonal antibody developed by Fast Forward Pharmaceuticals for the prevention of graft rejection. It is designed as a dual-targeting antagonist of the CD40-CD40L (CD154) pathway, simultaneously binding to both the CD40 receptor and its ligand. By blocking the interaction between CD40 and CD40L, FFP-106 inhibits the co-stimulatory signaling essential for T-cell activation and B-cell differentiation, thereby suppressing the immune-mediated rejection of transplanted organs. Clinical development of FFP-106 appears to have ceased following the developer, Fast Forward Pharmaceuticals, becoming inactive around 2019.
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD40LG (CD40 ligand extracellular domain)
Beyond the preview
Go deeper on FFP-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FFP-106.